GLP Audit Checklist

Generate an ALCOA+ data integrity checklist for GLP studies with 21 CFR Part 58 requirements mapped to your study scope and records.

Biotech / PharmaGLP ComplianceClient-Side

Try it out

Load example GLP audit checklist data to see the full workflow

Study Information

Audit Scope

Records to Audit

|
Required fields
  • Select at least one record category to audit.
  • Audit period start date must be YYYY-MM-DD format.
  • Audit period end date must be YYYY-MM-DD format.
  • Study title is required.
  • Study director name is required.
  • Facility name is required.
  • Pre-study QA readiness assessment
  • In-life phase audit preparation
  • End-of-study data integrity review before report issuance
  • Periodic GLP facility self-inspection

Don't use for

  • Non-GLP exploratory or discovery studies
  • Clinical trial data integrity (use ICH E6 GCP checklist)
  • Manufacturing GMP compliance (use 21 CFR Part 211)

Understanding ALCOA+ Data Integrity for GLP Studies

Data integrity is the foundation of GLP compliance. Regulatory agencies worldwide use the ALCOA+ framework to evaluate whether study data is trustworthy:

Attributable: Every data point must identify who generated it, when, and on what system. Electronic audit trails must capture user ID and timestamp for every action.
Legible: Data must be readable throughout its retention period. Handwritten data in permanent ink; electronic data in accessible formats. Corrections use single-line strikethrough — the original must remain readable.
Contemporaneous: Data recorded at the time of the activity. FDA inspectors compare instrument timestamps against study schedules to detect backdating.
Original: First recording or a certified true copy. "Transcribing" from unofficial notes to official forms is a common audit finding.
Accurate: Verified calculations, calibrated instruments, and consistent units. Selective reporting (cherry-picking favorable data) is a critical finding.
Complete, Consistent, Enduring, Available (the + in ALCOA+): No deleted data without justification, no contradictions between related records, durable storage media, and accessible archives.

The most common FDA 483 observations related to data integrity involve: missing audit trails on electronic systems, inadequate correction practices, and failure to retain original data.

Frequently Asked Questions